Nyhet från partner

ExpreS2ion’s CEO on current development and the rights issue

Nyhet från Biostock

Publicerad: 29 Mar 2023 08:45

ExpreS2ion Biotechnologies is eagerly awaiting top-line results from the phase III study with its Covid-19 vaccine.

Meanwhile the cancer vaccine candidate ES2B-C001 is advancing towards the clinic. BioStock spoke to CEO Bent U.

Frandsen to find out more about the development plans and the unit issue that will pave the way for further development.

The.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

•Denna källa har få eller inga artiklar bakom betalvägg

Läs hela artikeln hos Biostock

Nyhet från partner

ExpreS2ion’s CEO on current development and the rights issue

Nyhetsbrev